2024-12-01 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**1. Performance Comparison and Outperformance:**

Merck & Co Inc (MRK) is a leading pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare products.

The cumulative return of MRK (72.32%) significantly lags behind the S&P 500 (VOO) cumulative return (130.05%) over the analyzed period.  The difference is -57.7%, placing it at the 8.8th percentile of its historical range of underperformance relative to the S&P 500.  This indicates consistent underperformance compared to the broader market. The provided alpha consistently shows negative values (-0.1), further confirming underperformance relative to the market benchmark.  The beta, although varying, is consistently high indicating higher volatility than the S&P 500.


**2. Recent Price Movement:**

* **Closing Price:** $101.64
* **5-Day Moving Average:** $101.34
* **20-Day Moving Average:** $99.99
* **60-Day Moving Average:** $107.54

The price is slightly above the 20-day moving average but below the 60-day and 5-day averages, suggesting some short-term uncertainty. The recent closing price of 101.89 is not significantly different from the provided closing price, implying no major recent price jumps or drops.

**3. Technical Indicators and Expected Return:**

* **RSI:** 46.07 (Slightly below 50, suggesting a slightly bearish sentiment)
* **PPO:** 0.84 (Positive, indicating bullish momentum, but relatively low)
* **20-Day Relative Strength Change:** nan (-): Indicates a recent downward trend.
* **Expected Return:** 0.0% -  The provided 0% expected return indicates that based on the analysis, no significant excess return over the S&P 500 is expected over the long term (2+ years) through a buy-and-hold strategy.

**4. Recent Earnings Analysis:**

The provided earnings data shows some volatility in both EPS and revenue.  While revenue generally increased quarter-over-quarter, EPS fluctuated significantly, with a notable decline from $2.15 in Q2 2024 to $1.25 in Q3 2024. Further analysis would require comparing these figures to analyst expectations to determine whether these results were "beats" or "misses".  The repetition of the 2023-11-03 data suggests a potential error in the dataset.

**5. Financial Information Analysis:**

* **Revenue:** Shows a general upward trend, although there is a slight dip in the last quarter compared to the preceding one.
* **Profit Margin:** Generally high and stable, although it shows some minor fluctuations between quarters. A notable decrease can be seen from Q1 2024 to Q4 2023.
* **Equity:** Shows an upward trend throughout the periods.
* **ROE:**  Highly volatile with significant swings between positive and negative values, indicating variability in profitability.


**6. News and Recent Issues:**

No news or analyst opinions are provided.  Analysis of recent market outlook and analyst opinions is unavailable without additional information.

**7. Overall Analysis:**

MRK has shown consistent underperformance compared to the S&P 500 over the analyzed period, supported by a negative alpha. While the company displays generally strong revenue and profit margins,  EPS volatility and recent data on price suggest uncertainty. Technical indicators show mixed signals, with a slightly bearish RSI but positive, albeit weak, PPO.  The expected return of 0% suggests no significant outperformance is anticipated in the long run compared to the S&P 500.  Further investigation is needed to understand the reasons behind the EPS volatility and to compare reported earnings against analyst expectations. The missing news and analyst opinions prevent a comprehensive evaluation of current market sentiment and future expectations.  The incomplete and potentially erroneous earnings data needs clarification.


**8. Disclaimer:** This analysis is based solely on the provided data and should not be considered financial advice.  Independent research and consideration of individual risk tolerance are crucial before making any investment decisions.  The incompleteness and potential errors in the provided data limit the reliability of this analysis.
